

Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Schizophrenia: A Post Hoc Analysis

Roger S. McIntyre,¹ Desiree M. Matthews,² Marni E. Harris,³ Christina Arevalo,³ Martin Dunbar,³ David McDonnell,⁴ Christoph U. Correll^{1,5-7}

¹Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; ²Different Mental Health, Charlotte, NC, USA; ³Alkermes, Inc., Waltham, MA, USA; ⁴Alkermes Pharma Ireland Ltd., Dublin, Ireland; ⁵Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY, USA;

⁶Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine Hempstead, Hempstead, NY, USA; ⁷Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany

BACKGROUND

- Addressing negative symptoms in patients with schizophrenia is a treatment challenge
 - Negative symptoms of schizophrenia, including those related to reductions in motivation and interest (eg, avolition, anhedonia) or in expressive functions (eg, blunted affect, alogia), are associated with reduced functioning and are predictive of poor treatment response and functional outcomes¹
- The combination of olanzapine and samidorphan (OLZ/SAM) is approved in the United States for the treatment of adults with schizophrenia²
- OLZ/SAM significantly reduced Positive and Negative Syndrome Scale³ (PANSS) Total scores versus placebo in a randomized controlled study in patients with schizophrenia (ENLIGHTEN-1),⁴ with continued improvement observed over 52 weeks of open-label treatment in an extension study (ENLIGHTEN-1 Extension)⁵
- The objective of this post hoc analysis was to evaluate the effect of acute and long-term treatment with OLZ/SAM on negative symptoms of schizophrenia

METHODS


Patients

- Adult patients who completed a 4-week, olanzapine- and placebo-controlled study of OLZ/SAM for the treatment of acute schizophrenia⁴ (ENLIGHTEN-1, lead-in study; NCT02634346) and had ≥1 postbaseline visit in a 52-week open-label extension study⁵ (ENLIGHTEN-1 Extension, NCT02669758) were included in the post hoc analysis population (Figure 1)
- ENLIGHTEN-1 enrolled adult patients (18–70 years) experiencing an acute exacerbation or relapse of schizophrenia
 - Key inclusion criteria included PANSS Total score ≥80 at screening and baseline and score ≥4 on 3 or 4 of the following symptoms: delusions (item P1), conceptual disorganization (P2), hallucinatory behavior (P3), and suspiciousness/persecution (P6)

Study Design and Assessments

- Because the analysis focused on long-term effects, data were integrated across ENLIGHTEN-1 and ENLIGHTEN-1 Extension, and ENLIGHTEN-1 treatment groups (week 1–4 data for the OLZ/SAM, placebo, and olanzapine treatment groups) were combined for this analysis (Figure 1)

Figure 1. Study Design



^aPatients were randomized 1:1 to OLZ/SAM, olanzapine, or placebo. For patients in the olanzapine and OLZ/SAM treatment arms, the dose of olanzapine was 10 or 20 mg (target of 20 mg); the samidorphan dose was fixed at 10 mg.

^bPatients started on open-label OLZ/SAM 10/10 mg; dose could be increased to 15/10 or 20/10 mg during the first week of treatment or thereafter, based on investigator judgment.

^cPatients started on open-label OLZ/SAM 10/10 mg; dose could be increased to 15/10 or 20/10 mg during the first week of treatment or thereafter, based on investigator judgment.


DB, double-blind; OLZ/SAM, combination of olanzapine and samidorphan; PANSS, Positive and Negative Syndrome Scale.

- Negative symptoms were assessed based on PANSS Negative Symptoms Subscale³ and Marder Negative Symptoms Factor⁶ scores (Figure 2)
- Changes from baseline were evaluated for each postbaseline assessment, overall and among patients with high negative symptoms (PANSS Marder Negative Symptoms Factor score ≥24) at baseline
- To explore whether changes in negative symptoms were secondary to improvements in positive or other symptoms, a subgroup with high negative symptoms and low positive symptoms (PANSS Mohr Positive Symptoms Factor⁷ score ≤19) at baseline was included

Statistical Analysis


- Changes from baseline in PANSS Total, PANSS Negative Symptoms Subscale, and Marder Negative Symptoms Factor scores were summarized descriptively; no formal statistical testing was conducted

Figure 2. Item Composition of the PANSS Marder Negative Symptoms Factor and Mohr Positive Symptoms Factor^{6,7}




PANSS, Positive and Negative Syndrome Scale.

In this post hoc analysis, negative symptoms of schizophrenia decreased during short-term treatment and continued to decrease over 52 weeks of OLZ/SAM treatment, overall and among patients with high negative symptoms at baseline




Subgroup Analyses

Figure 5. Changes From Baseline in PANSS Negative Symptoms Subscale³ Score, High Baseline Negative Symptoms Subgroup^b



^aBlunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), difficulty in abstract thinking (N5), lack of spontaneity/flow of conversation (N6), and stereotyped thinking (N7). ^bPatients with a PANSS Marder Negative Symptoms Factor score ≥24 at baseline. PANSS, Positive and Negative Syndrome Scale.


Figure 4. Changes From Baseline in PANSS Marder Negative Symptoms Factor^a Score, Overall Post Hoc Analysis Population^b



^aBlunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity (N6), motor retardation (G7), and active social avoidance (G16).

^bPatients who had completed the 4-week ENLIGHTEN-1 lead-in study and had ≥1 postbaseline visit in the 52-week open-label ENLIGHTEN-1 Extension.

Figure 6. Changes From Baseline in PANSS Marder Negative Symptoms Factor^a Score, High Baseline Negative Symptoms^b and High Negative/Low Positive Symptoms Subgroups^c



^aBlunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and flow of conversation (N6), motor retardation (G7), and active social avoidance (G16). ^bPatients with a PANSS Marder Negative Symptoms Factor score ≥24 at baseline. ^cPatients with a PANSS Marder Negative Symptoms Factor score ≥24 at baseline; a baseline score ≥4 on at least 2 of the following 3 PANSS items: blunted affect (N1), passive/apathetic social withdrawal (N4), or lack of spontaneity and flow of conversation (N6); and a PANSS Mohr Positive Symptoms Factor score ≤19 at baseline. Mohr Positive Symptoms Factor: delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), and unusual thought content (G9).⁷ neg, negative; PANSS, Positive and Negative Syndrome Scale; pos, positive.

Patients

Table 1. Demographics and ENLIGHTEN-1 Study Baseline Clinical Characteristics, Post Hoc Analysis Population^a

Characteristics	All Patients (N=281)
Age, mean (SD), years	41.7 (11.6)
Sex, male, n (%)	160 (56.9)
Race, n (%)	
White	221 (78.6)
Black or African American	53 (18.9)
Asian	3 (1.1)
Other	4 (1.4)
BMI, mean (SD), kg/m ²	26.2 (4.9)
CGI-S score, mean (SD)	5.1 (0.7)
PANSS Total score, mean (SD)	101.7 (11.1)
PANSS Marder Negative Symptoms Factor ^b score, mean (SD)	25.2 (4.6)

^aPatients who had completed the 4-week ENLIGHTEN-1 lead-in study and had ≥1 postbaseline visit in the 52-week open-label ENLIGHTEN-1 Extension.

^bPANSS Marder Negative Symptoms Factor: blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity (N6), motor retardation (G7), and active social avoidance (G16).

BMI, body mass index; CGI-S, Clinical Global Impressions-Severity; PANSS, Positive and Negative Syndrome Scale.

LIMITATIONS

- The lack of a comparator in the ENLIGHTEN-1 Extension limits interpretation of the results
- The post hoc nature of this analysis of negative symptoms of schizophrenia limits interpretation of the results
- Treatment groups in the placebo-controlled 4-week study were combined in this analysis
- The number of patients who met the criteria for high negative symptoms and low positive symptoms at baseline was small
- Because the patients met specified enrollment criteria for ENLIGHTEN-1, results from this analysis may not be generalizable to the real-world population of patients with schizophrenia who are started on antipsychotic treatment

CONCLUSIONS

- In this post hoc analysis, negative symptoms of schizophrenia decreased during short-term treatment, and continued improvement was observed over 52 weeks of maintenance therapy with OLZ/SAM
- Improvement in negative symptoms was observed overall and among patients with high negative symptoms at baseline
- Improvement was similar for patients with high negative symptoms at baseline and those with high negative/low positive symptoms
- The clinical relevance of the observed improvement in negative symptom scores could not be determined directly because functional outcome assessments were not included in ENLIGHTEN-1 and the ENLIGHTEN-1 Extension
 - However, the 9-point change in PANSS Negative Symptoms Subscale score in the high negative symptoms subgroup is similar to clinically relevant reductions reported previously⁸

REFERENCES

- Correll CU, Schooler NR. *Neuropsychiatr Dis Treat*. 2020;16:519-34. DOI: [10.2147/ndt.S225643](https://doi.org/10.2147/ndt.S225643)
- Lybalvi [package insert]. Waltham, MA: Alkermes, Inc.; 2024.
- Kay SR, et al. *Schizophr Bull*. 1987;13(2):261-76. DOI: [10.1093/schbul/13.2.261](https://doi.org/10.1093/schbul/13.2.261)
- Potkin SG, et al. *J Clin Psychiatry*. 2020;81(2):19m12769. DOI: [10.4088/JCP.19m12769](https://doi.org/10.4088/JCP.19m12769)
- Yagoda S, et al. *CNS Spectr*. 2020;26(4):383-92. DOI: [10.1017/S1092852920001376](https://doi.org/10.1017/S1092852920001376)
- Marder SR, et al. *J Clin Psychiatry*. 1997;58(12):538-46. DOI: [10.4088/jcp.v58n1205](https://doi.org/10.4088/jcp.v58n1205)
- Mohr PE, et al. *Schizophr Res*. 2004;71(1):83-95. DOI: [10.1016/j.schres.2003.11.008](https://doi.org/10.1016/j.schres.2003.11.008)
- Németh G, et al. *Lancet*. 2017;389(10074):1103-13. DOI: [10.1016/S0140-6736\(17\)30060-0](https://doi.org/10.1016/S0140-6736(17)30060-0)

Disclosure information, acknowledgments, key contributors, and copies of this poster can be obtained through this QR (Quick Response) code. These materials are for personal use only and may not be reproduced without permission of Alkermes. For permission, contact USMedInfo@alkermes.com



Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Schizophrenia: A Post Hoc Analysis

Roger S. McIntyre,¹ Desiree M. Matthews,² Marni E. Harris,³ Christina Arevalo,³ Martin Dunbar,³ David McDonnell,⁴ Christoph U. Correll⁵⁻⁷

¹Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; ²Different Mental Health, Charlotte, NC, USA; ³Alkermes, Inc., Waltham, MA, USA; ⁴Alkermes Pharma Ireland Ltd., Dublin, Ireland; ⁵Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY, USA; ⁶Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine Hempstead, Hempstead, NY, USA; ⁷Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany

DISCLOSURES

RSM has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; has received speaker/consultation fees from AbbVie, Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, NeuraWell, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, and Viatrix; and is a CEO of Braxia Scientific Corp.

DMM has been a consultant and/or advisor to AbbVie, Alkermes, Biogen, Bristol Myers Squibb, Indivior, Janssen, Johnson & Johnson, Neurocrine Biosciences, Sage Therapeutics, and Teva; and has received speaker fees from AbbVie, Axsome Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lundbeck, Neurocrine Biosciences, Otsuka Pharmaceuticals, and Teva.

MEH, CA, and **MD** are or were employees of Alkermes, Inc., and may own stock/options in the company.

DM is or was an employee of Alkermes Pharma Ireland, Ltd, and may own stock/options in the company.

CUC has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedinCell, Merck, MindPax, Mitsubishi Tanabe Pharma, Mylan, Neurelis, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatrix; has provided expert testimony for Janssen and Otsuka; has served on a data safety monitoring board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva; has received grant support from Janssen and Takeda; has received royalties from UpToDate; and is a stock option holder of Cardio Diagnostics, Küleon Biosciences, LB Pharma, MindPax, and Quantic.

ACKNOWLEDGMENTS

Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.

Key Contributors

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the poster; gave final approval of the version to be presented; and agree to be accountable for all aspects of the work.